P. Papanastasiou

发表

Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52‐week results from a Phase 3 double‐blind randomized, controlled trial

C. Bodemer, K. Kingo, A. Kaszuba, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis.

P. Emery, P. Conaghan, A. Grainger, 2006, Arthritis and rheumatism.

Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled JUNCTURE trial

C. Paul, C. Papavassilis, J. Nyirady, 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids.

J. Reginster, P. Sambrook, D. Reid, 2013, Rheumatology.

Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis

P. Sambrook, D. Reid, K. Saag, 2012, Osteoporosis International.

The variant-specific surface protein of Giardia, VSP4A1, is a glycosylated and palmitoylated protein.

M. McConville, J. Ralton, P. Köhler, 1997, The Biochemical journal.

Bone histomorphometry analyses in glucocorticoid-induced osteoporosis patients treated with once-yearly zoledronic acid or oral risedronate over 1 year

R. Recker, D. Reid, D. Chappard, 2011 .

Reduction in incidence of vertebral fractures with once yearly zoledronic acid in men with osteoporosis

J. Reginster, R. Rizzoli, S. Boonen, 2011 .

Primary structure and biochemical properties of a variant-specific surface protein of Giardia.

Y. Li, P. Köhler, T. Bruderer, 1997, Molecular and biochemical parasitology.

The release of the variant surface protein of Giardia to its soluble isoform is mediated by the selective cleavage of the conserved carboxy-terminal domain.

P. Köhler, P. Papanastasiou, C. Bommeli, 1996, Biochemistry.

Fracture risk and zoledronic acid therapy in men with osteoporosis.

J. Reginster, R. Rizzoli, S. Boonen, 2012, The New England journal of medicine.

Variant cysteine-rich surface proteins of Giardia isolates from human and animal sources

P. Köhler, T. Bruderer, P. Papanastasiou, 1993, Infection and immunity.

Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data

A. Gottlieb, M. Lebwohl, A. Deodhar, 2022, Acta dermato-venereologica.

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial

J. Reginster, P. Sambrook, D. Reid, 2009, The Lancet.

Primary structure and biochemical properties of a variant-specific surface protein of Giardia1Note: The nucleotide sequence information reported in this paper has been submitted to the EMBL Data Library with the accession No. Z83743.1

P. Köhler, T. Bruderer, Yajie Li, 1997 .

Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1–34)] in postmenopausal osteoporosis

S. Boonen, P. Miller, E. Eriksen, 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study

J. Szepietowski, K. Kingo, W. Bao, 2022, Pediatric Drugs.